XML 30 R23.htm IDEA: XBRL DOCUMENT v3.24.3
Income Tax Expense (Benefit)
 9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
Income Tax Expense (Benefit)

14. INCOME TAX EXPENSE (BENEFIT)

The Company recorded an income tax expense of $4.7 million and $10.0 million for the three and nine months ended September 30, 2024, respectively, compared to an income tax expense of $2.3 million and an income tax benefit of $4.3 million for the three months and nine months ended September 30, 2023, respectively. The effective tax rate for the three and nine months ended September 30, 2024, was 28.1% and 28.8%, respectively. The effective tax rate for the three and nine months ended September 30, 2023 was 20.0% and (14.4%), respectively. The tax rate for the three and nine months ended September 30, 2024 was impacted by the earnings mix of jurisdictions subject to tax for the period and items discrete to the quarter. The tax rate for the nine months ended September 30, 2023 was largely impacted by the reversal of net deferred tax liabilities attributable to Core Laboratories N.V., which were not realized following the Redomestication Transaction on May 1, 2023.